Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6919437 | 0.69 | — | — | |
| SCHEMBL8339258 | 0.63 | BACE1 (0.32) | TDP1 | |
| SCHEMBL11680905 | 0.61 | — | — | |
| SCHEMBL7364626 | 0.61 | — | — | |
| SCHEMBL13527924 | 0.56 | TDP1 (0.80) | TDP1ALDH1A1MAPT | |
| SCHEMBL131371 | 0.54 | TSHR (0.39) | MAPT | |
| SCHEMBL133284 | 0.54 | HSD17B10 (0.39) | MAPT | |
| SCHEMBL9211477 | 0.54 | TSHR (0.39) | MAPT | |
| SCHEMBL2893149 | 0.54 | TSHR (0.39) | MAPT | |
| SCHEMBL367457 | 0.54 | TSHR (0.52) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3604308-B1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2023-09-13 | — | — | EP | disclosed |
| EP-3539952-B1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2022-06-22 | — | — | EP | disclosed |
| CN-107253933-B | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | 勃林格殷格翰国际有限公司 | 2021-10-26 | — | — | CN | disclosed |
| EP-3604308-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | Boehringer Ingelheim International GmbH (DE) | 2020-02-05 | — | — | EP | disclosed |
| EP-3174862-B1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2019-10-23 | — | — | EP | disclosed |
| EP-3539952-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | Boehringer Ingelheim International GmbH (DE) | 2019-09-18 | — | — | EP | disclosed |
| US-RE47493-E1 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-07-09 | — | — | US | disclosed |
| EP-3174861-B1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2019-05-15 | — | — | EP | disclosed |
| EP-3174863-B1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2018-12-05 | — | — | EP | disclosed |
| EP-3174860-B1 | SUBSTITUTED DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2018-09-19 | — | — | EP | disclosed |
| EP-2234985-B1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | Bayer Pharma AG (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20120004203-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-05 | — | — | US | disclosed |
| EP-2385945-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | Bayer Pharma Aktiengesellschaft (DE) | 2011-11-16 | — | — | EP | disclosed |
| US-8041896-B2 | Virtualization platform with dedicated cache access | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110118221-A1 | 1,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-19 | — | — | US | disclosed |
| EP-2285809-A1 | 1,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-02-23 | — | — | EP | disclosed |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| WO-2010078953-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-15 | — | — | WO | disclosed |
| WO-2009135599-A1 | 1,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-12 | — | — | WO | disclosed |
| CN-101479270-A | Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors | ARGENTA DISCOVERY LTD (GB) | 2009-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118221-A1 | 1,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE | QDPR, DPYD, DPP4 | TDP1 416/4885ALDH1A1 290/4885MAPT 4656/4885 |
| US-20120004203-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | KEAP1, NOX4, NOX5 | TDP1 977/4885ALDH1A1 197/4885MAPT 2705/4885 |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | TNNI3, TNNT2, PC | TDP1 1656/4885ALDH1A1 616/4885MAPT 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.